These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells. Hirano S; Udagawa O Arch Toxicol; 2022 Feb; 96(2):545-558. PubMed ID: 35001170 [TBL] [Abstract][Full Text] [Related]
5. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML. Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103 [TBL] [Abstract][Full Text] [Related]
6. Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation. Saito Â; Souza EE; Costa FC; Meirelles GV; Gonçalves KA; Santos MT; Bressan GC; McComb ME; Costello CE; Whelan SA; Kobarg J J Proteome Res; 2017 Sep; 16(9):3147-3157. PubMed ID: 28695742 [TBL] [Abstract][Full Text] [Related]
7. An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16. Bund T; Spoden GA; Koynov K; Hellmann N; Boukhallouk F; Arnold P; Hinderberger D; Florin L Cell Microbiol; 2014 Aug; 16(8):1179-200. PubMed ID: 24444361 [TBL] [Abstract][Full Text] [Related]
8. Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3. Evdokimov E; Sharma P; Lockett SJ; Lualdi M; Kuehn MR J Cell Sci; 2008 Dec; 121(Pt 24):4106-13. PubMed ID: 19033381 [TBL] [Abstract][Full Text] [Related]
15. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells. Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586 [TBL] [Abstract][Full Text] [Related]
16. The SUMO2/3 specific E3 ligase ZNF451-1 regulates PML stability. Koidl S; Eisenhardt N; Fatouros C; Droescher M; Chaugule VK; Pichler A Int J Biochem Cell Biol; 2016 Oct; 79():478-487. PubMed ID: 27343429 [TBL] [Abstract][Full Text] [Related]
17. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation. Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659 [TBL] [Abstract][Full Text] [Related]
18. SUMO promotes DNA repair protein collaboration to support alternative telomere lengthening in the absence of PML. Zhao R; Xu M; Yu X; Wondisford AR; Lackner RM; Salsman J; Dellaire G; Chenoweth DM; O'Sullivan RJ; Zhao X; Zhang H Genes Dev; 2024 Aug; 38(13-14):614-630. PubMed ID: 39038850 [TBL] [Abstract][Full Text] [Related]
19. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Song J; Durrin LK; Wilkinson TA; Krontiris TG; Chen Y Proc Natl Acad Sci U S A; 2004 Oct; 101(40):14373-8. PubMed ID: 15388847 [TBL] [Abstract][Full Text] [Related]
20. Identification and Characterization of SUMO-SIM Interactions. Husnjak K; Keiten-Schmitz J; Müller S Methods Mol Biol; 2016; 1475():79-98. PubMed ID: 27631799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]